The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo
作者： Aymen I. Idris , Euphemie Landao-Bassonga , Stuart H. Ralston
DOI: 10.1016/J.BONE.2010.01.368
关键词:
摘要: The vanilloid type 1 ion channel (TRPV1) is known to play an important role in the regulation of pain and inflammation. Pharmacological ligands TRPV1 regulate human osteoclast formation vitro, but effects these agents on osteoblast function have not been studied their bone loss vivo are unknown. Here we examined antagonist capsazepine mouse differentiation vitro ovariectomy induced vivo. Capsazepine inhibited resorption a dose dependent manner marrow–osteoblast co-cultures RANKL generated cultures, whereas agonist capsaicin enhanced M-CSF stimulated formation. also suppressed IκB ERK1/2 phosphorylation caused apoptosis mature osteoclasts alkaline phosphatase activity nodule calvarial cultures. Studies showed that (1 mg/kg/day) mice histomorphometric analysis inhibitory indices We conclude pharmacological blockade channels by inhibits osteoclastic protects against mice,
elsevier.com
ed.ac.uk 
sci-hub.se 参考文章(59)
Aymen I Idris, Role of cannabinoid receptors in bone disorders: alternatives for treatment. Drug News & Perspectives. ,vol. 21, pp. 533- 540 ,(2008) , 10.1358/DNP.2008.21.10.1314055
Robert J. van t' Hof, Osteoclast Formation in the Mouse Coculture Assay Bone Research Protocols. ,vol. 80, pp. 145- 152 ,(2003) , 10.1385/1-59259-366-6:145
Bone research protocols Humana Press. ,(2003) , 10.1007/978-1-61779-415-5
Y. Chen, H.H. Willcockson, J.G. Valtschanoff, Vanilloid receptor TRPV1-mediated phosphorylation of ERK in murine adjuvant arthritis. Osteoarthritis and Cartilage. ,vol. 17, pp. 244- 251 ,(2009) , 10.1016/J.JOCA.2008.06.015
JH Tobias, JWM Chow, TJ Chambers, None, 3-Amino-1-hydroxypropylidine-1-bisphosphonate (AHPrBP) suppresses not only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone Bone. ,vol. 14, pp. 619- 623 ,(1993) , 10.1016/8756-3282(93)90083-M
P.D. Delmas, P. Vergnaud, M.E. Arlot, P. Pastoureau, P.J. Meunier, M.H.L. Nilssen, The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone. ,vol. 16, pp. 603- 610 ,(1995) , 10.1016/8756-3282(95)00113-R
R J Docherty, J C Yeats, A S Piper, Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture British Journal of Pharmacology. ,vol. 121, pp. 1461- 1467 ,(1997) , 10.1038/SJ.BJP.0701272
Gilbert Y. Wong, Narender R. Gavva, Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Research Reviews. ,vol. 60, pp. 267- 277 ,(2009) , 10.1016/J.BRAINRESREV.2008.12.006
Aymen I. Idris, Antonia Sophocleous, Euphemie Landao-Bassonga, Meritxell Canals, Graeme Milligan, David Baker, Robert J. van't Hof, Stuart H. Ralston, Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells Cell Metabolism. ,vol. 10, pp. 139- 147 ,(2009) , 10.1016/J.CMET.2009.07.006
L Liu, S.A Simon, Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia Neuroscience Letters. ,vol. 228, pp. 29- 32 ,(1997) , 10.1016/S0304-3940(97)00358-3